COVID-19 vaccine doses and administration

The following COVID-19 vaccines have been provisionally approved for use in Australia. Find out their dosage, volume and schedules.

Pfizer (Comirnaty) ≥12 years formulation – generic name tozinameran or BNT162b2

Category

Detail

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

≥12 years

Presentation

Multidose vial without preservative. Each vial contains 6 doses in 0.45 mL. Requires dilution with 1.8 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour

Purple

Volume/strength

0.3 mL (30 µg) per dose

Schedule

2 doses, 3 to 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.3 mL dose contains 30 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • distearoylphosphatidylcholine (DSPC)
  • cholesterol
  • potassium chloride
  • monobasic potassium phosphate
  • sodium chloride
  • dibasic sodium phosphate dihydrate
  • sucrose
  • water for injection

Pfizer (Comirnaty) 5 to 11 years formulation – generic name tozinameran or BNT162b2

Category

Detail

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

5 to <12 years

Presentation

Tris/sucrose presentation. Multidose vial containing 10 doses in 1.3 mL. Requires dilution with 1.3 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour

Orange

Volume/strength

0.2 mL (10 µg) per dose

Schedule

2 doses, 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.2 mL dose contains 10 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • distearoylphosphatidylcholine (DSPC)
  • cholesterol
  • trometamol
  • trometamol hydrochloride
  • sucrose
  • water for injection

Pfizer (Comirnaty) 6 months to 4 years formulation – generic name tozinameran or BNT162b2

Category Detail

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

6 months to <5 years

Presentation

Tris/sucrose presentation. Multidose vial containing 10 doses in 0.4 mL. Requires dilution with 2.2 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour

Maroon

Volume/strength

0.2 mL (3 µg) per dose

Schedule

3 doses, each dose 8 weeks apart

Administration route

For infants aged 6 to 12 months: Intramuscular injection into vastus lateralis muscle of the anterolateral thigh

For children aged ≥12 months: Intramuscular injection into deltoid muscle (or into the vastus lateralis muscle of the anterolateral thigh)

Ingredients

Each 0.2 mL dose contains 3 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • distearoylphosphatidylcholine (DSPC)
  • cholesterol
  • trometamol
  • trometamol hydrochloride
  • sucrose
  • water for injection

Pfizer (Comirnaty) bivalent original/Omicron BA.1 ≥18 years formulation – generic name tozinameran or BNT162b2 (OMI) BA.1

Category

Detail

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

≥18 years

Presentation

Multidose vial containing 6 doses of 0.3 mL. Does not require dilution

Cap colour

Grey

Volume/strength

0.3 mL (30 µg) per dose

Schedule

1 dose

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.3 mL dose contains 15 µg of tozinameran and 15 µg of riltozinameran

Excipients

  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis (2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • distearoylphosphatidylcholine (DSPC)
  • cholesterol
  • trometamol
  • trometamol hydrochloride
  • sucrose
  • water for injection

Moderna (Spikevax) original ≥ 6 years formulation – generic name elasomeran or mRNA-1273

Category

Detail

Sponsor

Moderna Australia Pty Ltd

Approved age for use

≥6 years

Presentation

5 mL multidose vial without preservative

Cap colour

Red

Volume/strength

For children aged 6 to 11 years: 0.25 mL per dose

For people aged ≥12 years as a primary course: 0.5 mL per dose

For people aged ≥18 years as a booster: 0.25 mL per dose

Schedule

For children aged 6 to 11 years: 2 doses, 8 weeks apart

For people aged ≥12 years: 2 doses, 4 to 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 100 μg mRNA encoding the SARS-CoV-2 spike glycoprotein (50 ug in each 0.25 mL dose)

Excipients

  • heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
  • cholesterol
  • distearoylphosphatidylcholine
  • 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
  • trometamol
  • trometamol hydrochloride
  • acetic acid
  • sodium acetate trihydrate
  • sucrose
  • water for injection

Moderna (Spikevax) 6 months to 5 years formulation – generic name elasomeran or mRNA-1273

Category

Detail

Sponsor

Moderna Australia Pty Ltd

Approved age for use

6 months to 5 years

Presentation

2.5 mL multidose vial without preservative

Cap colour

Blue. Note that the Moderna bivalent vaccine also has a blue cap. To minimise the risk of administration errors, providers should preferably prepare and store doses of these vaccines separately. Doses withdrawn in advance of administration should be clearly labelled.

Volume/strength

0.25 mL per dose

Schedule

2 doses, 8 weeks apart

Administration route

For infants aged <12 months: Intramuscular injection into vastus lateralis muscle of the anterolateral thigh

For children aged ≥12 months: Intramuscular injection into deltoid muscle (or into the vastus lateralis muscle of the anterolateral thigh)

Ingredients

Each 0.25 mL dose contains 25 μg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
  • cholesterol
  • distearoylphosphatidylcholine
  • 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
  • trometamol
  • trometamol hydrochloride
  • acetic acid
  • sodium acetate trihydrate
  • sucrose
  • water for injection

Moderna (Spikevax) bivalent 18 years and older – generic name elasomeran/imelasomeran or mRNA-1273.214

Category

Detail

Sponsor

Moderna Australia Pty Ltd

Approved age for use

≥18 years

Presentation

2.5 mL multidose vial without preservative

Cap colour

Blue. Note that the Moderna 6 months to 5 years formulation also has a blue cap. To minimise the risk of administration errors, providers should preferably prepare and store doses of these vaccines separately. Doses withdrawn in advance of administration should be clearly labelled.

Volume/strength

0.5 mL per dose

Schedule

1 dose, 3 months after last dose

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 25 μg elasomeran (ancestral SARS-CoV-2) and 25 μg imlasomeran (Omicron BA.1 subvariant)

Excipients

  • heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
  • cholesterol
  • distearoylphosphatidylcholine
  • 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
  • trometamol
  • trometamol hydrochloride
  • acetic acid
  • sodium acetate trihydrate
  • sucrose
  • water for injection

AstraZeneca (Vaxzevria) – generic name ChAdOx1s

Category

Detail

Sponsor

AstraZeneca Pty Ltd

Approved age for use

≥18 years

Presentation

Multidose vial without preservative, each vial containing either 8 doses in 4 mL or 10 doses in 5 mL

Volume/strength

0.5 mL per dose

Schedule

2 doses, 4 to 12 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 5 x 1010 viral particles of ChAdOx1-S, a recombinant, non-replicating chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • histidine
  • histidine hydrochloride monohydrate
  • sodium chloride
  • magnesium chloride hexahydrate
  • disodium edetate (EDTA)
  • sucrose
  • ethanol absolute
  • polysorbate 80
  • water for injection

Novavax (Nuvaxovid) – generic name NVX-CoV2373

Category

Detail

Sponsor

Biocelect Pty Ltd on behalf of Novavax Ltd

Approved age for use

≥12 years

Presentation

Multidose vial without preservative, each vial containing 10 doses in 5 mL

Volume/strength

5 µg antigen, 50 µg Matrix-M

Schedule

2 doses, 3 to 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 5 µg of SARS-CoV-2 spike protein, adjuvanted with Matrix-M.

Adjuvant Matrix-M contains Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract

Excipients

  • dibasic sodium phosphate heptahydrate
  • monobasic sodium phosphate monohydrate
  • sodium chloride
  • polysorbate 80
  • sodium hydroxide (for adjustment of pH)
  • hydrochloric acid (for adjustment of pH)
  • water for injection
  • adjuvant (Matrix M)
    • Quillaja saponaria saponins fraction A
    • Quillaja saponaria saponins fraction C
    • cholesterol
    • phosphatidyl choline
    • monobasic potassium phosphate
    • potassium chloride
Last updated:

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.